首站-论文投稿智能助手
典型文献
Research and development of Chinese anti-COVID-19 drugs
文献摘要:
The outbreak and spread of coronavirus disease 2019(COVID-19)highlighted the impor-tance and urgency of the research and development of therapeutic drugs.Very early into the COVID-19 pandemic,China has begun developing drugs,with some notable progress.Herein,we summarizes the anti-COVID-19 drugs and promising drug candidates originally developed and researched in China.Furthermore,we discussed the developmental prospects,mechanisms of action,and advantages and dis-advantages of the anti-COVID-19 drugs in development,with the aim to contribute to the rational use of drugs in COVID-19 treatment and more effective development of new drugs against severe acute respi-ratory syndrome coronavirus 2(SARS-CoV-2)and the variants.Neutralizing antibody is an effective approach to overcome COVID-19.However,drug resistance induced by rapid virus mutation will likely to challenge neutralizing antibodies.Taking into account current epidemic trends,small molecule drugs have a crucial role in fighting COVID-19 due to their significant advantage of convenient administration and affordable and broad-spectrum.Traditional Chinese medicines,including natural products and tradi-tional Chinese medicine prescriptions,contribute to the treatment of COVID-19 due to their unique mechanism of action.Currently,the research and development of Chinese anti-COVID-19 drugs have led to some promising achievements,thus prompting us to expect even more rapidly available solutions.
文献关键词:
作者姓名:
Xiwei Ji;Xiangrui Meng;Xiao Zhu;Qingfeng He;Yimin Cui
作者机构:
Institute of Clinical Pharmacology,Peking University First Hospital,Beijing 100034,China;Xiyuan Hospital,China Academy of Chinese Medical Sciences,Beijing 100091,China;Department of Clinical Pharmacy and Pharmacy Administration,School of Pharmacy,Fudan University,Shanghai 201203,China
引用格式:
[1]Xiwei Ji;Xiangrui Meng;Xiao Zhu;Qingfeng He;Yimin Cui-.Research and development of Chinese anti-COVID-19 drugs)[J].药学学报(英文版),2022(12):4271-4286
A类:
B类:
Research,Chinese,drugs,outbreak,spread,coronavirus,disease,highlighted,impor,urgency,therapeutic,Very,early,into,pandemic,China,has,begun,developing,some,notable,progress,Herein,summarizes,promising,candidates,originally,developed,researched,Furthermore,discussed,developmental,prospects,mechanisms,action,advantages,aim,contribute,rational,use,treatment,effective,new,against,severe,acute,respi,ratory,syndrome,SARS,CoV,variants,Neutralizing,antibody,approach,overcome,However,resistance,induced,by,mutation,will,likely,challenge,neutralizing,antibodies,Taking,account,current,epidemic,trends,small,molecule,have,crucial,role,fighting,due,their,significant,convenient,administration,affordable,broad,spectrum,Traditional,medicines,including,natural,products,tradi,prescriptions,unique,Currently,led,achievements,thus,prompting,expect,even,rapidly,available,solutions
AB值:
0.5887
相似文献
Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants
Jia Lu;Qiangling Yin;Rongjuan Pei;Qiu Zhang;Yuanyuan Qu;Yongbing Pan;Lina Sun;Ding Gao;Cuiqin Liang;Jingwen Yang;Wei Wu;Jiandong Li;Zongqiang Cui;Zejun Wang;Xinguo Li;Dexin Li;Shiwen Wang;Kai Duan;Wuxiang Guan;Mifang Lian;Xiaoming Yang-National Engineering Technology Research Center for Combined Vaccines,Wuhan Institute of Biological Products Co.Ltd.,Wuhan,430070,China;State Key Laboratory for Molecular Virology and Genetic Engineering National Institute for Viral Disease Control and Prevention,Chinese Center for Disease Control and Prevention,Beijing,102206,China;Center for Emerging Infectious Diseases,Wuhan Institute of Virology,Chinese Academy of Sciences,Wuhan,430071,China;CDC-WIV Joint Research Center for Emerging Diseases and Biosafety,Wuhan,430071,China;Institution of Infectious Diseases,Shenzhen Bay Laboratory,Shenzhen,518107,China
Early assessment of the safety and immunogenicity of a third dose(booster)of COVID-19 immunization in Chinese adults
Yuntao Zhang;Yunkai Yang;Niu Qiao;Xuewei Wang;Ling Ding;Xiujuan Zhu;Yu Liang;Zibo Han;Feng Liu;Xinxin Zhang;Xiaoming Yang-China National Biotec Group Company Limited,Beijing 100024,China;Shanghai Institute of Hematology,State Key Laboratory of Medical Genomics,National Research Center for Translational Medicine at Shanghai,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Beijing Institute of Biological Products,China National Biotec Group Company Limited,Beijing 100176,China;National Vaccine and Serum Institute,China National Biotec Group Company Limited,Beijing 101111,China;Department of Infectious Diseases,Research Laboratory of Clinical Virology,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。